Filing Flows › Comparisons › ETON vs PBYI
Eton Pharmaceuticals vs Puma Biotechnology: ETON and PBYI compared
Eton Pharmaceuticals is the larger company: $57.9M of revenue in its latest quarter (Q3 2026) against $55.1M for Puma Biotechnology (Q3 2026). Eton Pharmaceuticals is growing faster (+158% against +1% a year earlier). Eton Pharmaceuticals is more profitable, with an operating margin of 39.7% against 9.6%.
Where the money goes: ETON and PBYI
Eton Pharmaceuticals (ETON) · Q3 2026
Eton Pharmaceuticals, Q3 2026: revenue $57.9M (+158% year over year), operating margin 39.7%, net earnings $35.2M, operating cash flow $35.2M. The chart follows the revenue to costs, profit and cash.
Puma Biotechnology (PBYI) · Q3 2026
Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%, net earnings $6.0M. The chart follows the revenue to costs, profit and cash.
| Eton Pharmaceuticals (ETON) | Puma Biotechnology (PBYI) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $57.9M | $55.1M |
| Revenue growth, Y/Y | +158% | +1% |
| Gross margin | 76.5% | — |
| Operating margin | 39.7% | 9.6% |
| Net earnings | $35.2M | $6.0M |
| Net margin | 60.9% | 10.9% |
| Operating cash flow | $35.2M | — |
| Free cash flow | $35.2M | — |
Where the revenue comes from
Puma Biotechnology
- Product revenue, net: $54.1M (98%)
- Royalty revenue: $1.0M (2%)
Questions
Which is bigger, Eton Pharmaceuticals or Puma Biotechnology?
Eton Pharmaceuticals is the larger company: $57.9M of revenue in its latest quarter (Q3 2026) against $55.1M for Puma Biotechnology (Q3 2026).
Is Eton Pharmaceuticals or Puma Biotechnology growing faster?
Eton Pharmaceuticals is growing faster (+158% against +1% a year earlier).
Which is more profitable, Eton Pharmaceuticals or Puma Biotechnology?
Eton Pharmaceuticals is more profitable, with an operating margin of 39.7% against 9.6%.
More: Eton Pharmaceuticals earnings · how Eton Pharmaceuticals makes money · Puma Biotechnology earnings · how Puma Biotechnology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 8-K filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.